

## Press Release

### **Astellas Named to FTSE4Good Index Series for 10 Consecutive Years**

**TOKYO, July 13, 2021** – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for 10 consecutive years, as a company that is performing excellent initiatives in the areas of ESG [environmental (E), social (S), governance (G)].

Astellas has conducted various activities based on the thought that Astellas’ contribution to the sustainability of society means the realization its philosophy. These sustained activities led Astellas to recognize and to be selected in such for a decade.

In the year ended 31 March 2021, Astellas reviewed its past activities and formulated its basic sustainability policy, which aims to improve the sustainability of both the global society and Astellas with the ESG in mind, instead of the conventional CSR-Based management. Astellas is working to further conduct its sustainability activities and expand its information disclosure<sup>\*1</sup>.

Astellas has set "Deepen our Engagement in Sustainability" as one of its new strategic goals in its Corporate Strategic Plan 2021<sup>\*2</sup>. In addition to implementing "Value Protection" which is an initiative to comply with regulations and meet the requirements from the global society, Astellas will further strengthen "Value Creation" activities to provide its patients’ access to innovative therapeutics and take proactive measures to conserve the global environment.

Besides the FTSE4Good Index Series, Astellas also has been named to all ESG investment indices selected by the Government Pension Investment Fund of Japan. These are the FTSE Blossom Japan Index, the MSCI Japan ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN), and the S&P/JPX Carbon Efficient Index.

Astellas will continue to work under its basic policy of sustainability, which is to improve the sustainability of both the global society and Astellas while keeping ESG in mind.



\*1: Astellas Corporate website “Sustainability Approach”. Available at:

<https://www.astellas.com/jp/en/sustainability/sustainability-approach>

\*2: Astellas Corporate website “Corporate Strategic Plan 2021”. Available at:

<https://www.astellas.com/jp/en/investors/strategic-plan>

### **About the FTSE4Good Index Series**

The FTSE4Good Index Series, developed by FTSE Russell, is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good Indices are used by a wide variety of market participants to create and assess sustainable investment funds and other products. FTSE Russell is a global index leader and wholly owned by London Stock Exchange Group.

### **About Astellas**

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at <https://www.astellas.com/en>.

### **Cautionary Notes**

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

---

### **Contacts for inquiries or additional information:**

Astellas Pharma Inc.  
Corporate Advocacy & Relations  
TEL: +81-3-3244-3201